Cargando…
Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia
OBJECTIVE: To investigate serum neurofilament light chain (NfL) concentrations in frontotemporal dementia (FTD) and to see whether they are associated with the severity of disease. METHODS: Serum samples were collected from 74 participants (34 with behavioral variant FTD [bvFTD], 3 with FTD and moto...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047041/ https://www.ncbi.nlm.nih.gov/pubmed/27581216 http://dx.doi.org/10.1212/WNL.0000000000003154 |
_version_ | 1782457384008941568 |
---|---|
author | Rohrer, Jonathan D. Woollacott, Ione O.C. Dick, Katrina M. Brotherhood, Emilie Gordon, Elizabeth Fellows, Alexander Toombs, Jamie Druyeh, Ronald Cardoso, M. Jorge Ourselin, Sebastien Nicholas, Jennifer M. Norgren, Niklas Mead, Simon Andreasson, Ulf Blennow, Kaj Schott, Jonathan M. Fox, Nick C. Warren, Jason D. Zetterberg, Henrik |
author_facet | Rohrer, Jonathan D. Woollacott, Ione O.C. Dick, Katrina M. Brotherhood, Emilie Gordon, Elizabeth Fellows, Alexander Toombs, Jamie Druyeh, Ronald Cardoso, M. Jorge Ourselin, Sebastien Nicholas, Jennifer M. Norgren, Niklas Mead, Simon Andreasson, Ulf Blennow, Kaj Schott, Jonathan M. Fox, Nick C. Warren, Jason D. Zetterberg, Henrik |
author_sort | Rohrer, Jonathan D. |
collection | PubMed |
description | OBJECTIVE: To investigate serum neurofilament light chain (NfL) concentrations in frontotemporal dementia (FTD) and to see whether they are associated with the severity of disease. METHODS: Serum samples were collected from 74 participants (34 with behavioral variant FTD [bvFTD], 3 with FTD and motor neuron disease and 37 with primary progressive aphasia [PPA]) and 28 healthy controls. Twenty-four of the FTD participants carried a pathogenic mutation in C9orf72 (9), microtubule-associated protein tau (MAPT; 11), or progranulin (GRN; 4). Serum NfL concentrations were determined with the NF-Light kit transferred onto the single-molecule array platform and compared between FTD and healthy controls and between the FTD clinical and genetic subtypes. We also assessed the relationship between NfL concentrations and measures of cognition and brain volume. RESULTS: Serum NfL concentrations were higher in patients with FTD overall (mean 77.9 pg/mL [SD 51.3 pg/mL]) than controls (19.6 pg/mL [SD 8.2 pg/mL]; p < 0.001). Concentrations were also significantly higher in bvFTD (57.8 pg/mL [SD 33.1 pg/mL]) and both the semantic and nonfluent variants of PPA (95.9 and 82.5 pg/mL [SD 33.0 and 33.8 pg/mL], respectively) compared with controls and in semantic variant PPA compared with logopenic variant PPA. Concentrations were significantly higher than controls in both the C9orf72 and MAPT subgroups (79.2 and 40.5 pg/mL [SD 48.2 and 20.9 pg/mL], respectively) with a trend to a higher level in the GRN subgroup (138.5 pg/mL [SD 103.3 pg/mL). However, there was variability within all groups. Serum concentrations correlated particularly with frontal lobe atrophy rate (r = 0.53, p = 0.003). CONCLUSIONS: Increased serum NfL concentrations are seen in FTD but show wide variability within each clinical and genetic group. Higher concentrations may reflect the intensity of the disease in FTD and are associated with more rapid atrophy of the frontal lobes. |
format | Online Article Text |
id | pubmed-5047041 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-50470412016-10-13 Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia Rohrer, Jonathan D. Woollacott, Ione O.C. Dick, Katrina M. Brotherhood, Emilie Gordon, Elizabeth Fellows, Alexander Toombs, Jamie Druyeh, Ronald Cardoso, M. Jorge Ourselin, Sebastien Nicholas, Jennifer M. Norgren, Niklas Mead, Simon Andreasson, Ulf Blennow, Kaj Schott, Jonathan M. Fox, Nick C. Warren, Jason D. Zetterberg, Henrik Neurology Article OBJECTIVE: To investigate serum neurofilament light chain (NfL) concentrations in frontotemporal dementia (FTD) and to see whether they are associated with the severity of disease. METHODS: Serum samples were collected from 74 participants (34 with behavioral variant FTD [bvFTD], 3 with FTD and motor neuron disease and 37 with primary progressive aphasia [PPA]) and 28 healthy controls. Twenty-four of the FTD participants carried a pathogenic mutation in C9orf72 (9), microtubule-associated protein tau (MAPT; 11), or progranulin (GRN; 4). Serum NfL concentrations were determined with the NF-Light kit transferred onto the single-molecule array platform and compared between FTD and healthy controls and between the FTD clinical and genetic subtypes. We also assessed the relationship between NfL concentrations and measures of cognition and brain volume. RESULTS: Serum NfL concentrations were higher in patients with FTD overall (mean 77.9 pg/mL [SD 51.3 pg/mL]) than controls (19.6 pg/mL [SD 8.2 pg/mL]; p < 0.001). Concentrations were also significantly higher in bvFTD (57.8 pg/mL [SD 33.1 pg/mL]) and both the semantic and nonfluent variants of PPA (95.9 and 82.5 pg/mL [SD 33.0 and 33.8 pg/mL], respectively) compared with controls and in semantic variant PPA compared with logopenic variant PPA. Concentrations were significantly higher than controls in both the C9orf72 and MAPT subgroups (79.2 and 40.5 pg/mL [SD 48.2 and 20.9 pg/mL], respectively) with a trend to a higher level in the GRN subgroup (138.5 pg/mL [SD 103.3 pg/mL). However, there was variability within all groups. Serum concentrations correlated particularly with frontal lobe atrophy rate (r = 0.53, p = 0.003). CONCLUSIONS: Increased serum NfL concentrations are seen in FTD but show wide variability within each clinical and genetic group. Higher concentrations may reflect the intensity of the disease in FTD and are associated with more rapid atrophy of the frontal lobes. Lippincott Williams & Wilkins 2016-09-27 /pmc/articles/PMC5047041/ /pubmed/27581216 http://dx.doi.org/10.1212/WNL.0000000000003154 Text en © 2016 American Academy of Neurology https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Article Rohrer, Jonathan D. Woollacott, Ione O.C. Dick, Katrina M. Brotherhood, Emilie Gordon, Elizabeth Fellows, Alexander Toombs, Jamie Druyeh, Ronald Cardoso, M. Jorge Ourselin, Sebastien Nicholas, Jennifer M. Norgren, Niklas Mead, Simon Andreasson, Ulf Blennow, Kaj Schott, Jonathan M. Fox, Nick C. Warren, Jason D. Zetterberg, Henrik Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia |
title | Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia |
title_full | Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia |
title_fullStr | Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia |
title_full_unstemmed | Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia |
title_short | Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia |
title_sort | serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047041/ https://www.ncbi.nlm.nih.gov/pubmed/27581216 http://dx.doi.org/10.1212/WNL.0000000000003154 |
work_keys_str_mv | AT rohrerjonathand serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia AT woollacottioneoc serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia AT dickkatrinam serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia AT brotherhoodemilie serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia AT gordonelizabeth serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia AT fellowsalexander serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia AT toombsjamie serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia AT druyehronald serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia AT cardosomjorge serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia AT ourselinsebastien serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia AT nicholasjenniferm serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia AT norgrenniklas serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia AT meadsimon serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia AT andreassonulf serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia AT blennowkaj serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia AT schottjonathanm serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia AT foxnickc serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia AT warrenjasond serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia AT zetterberghenrik serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia |